Biomm (BIOM3) Q1 2025 earnings summary

Executive summary

• 1Q25 net revenue rose 3% YoY to R$39,591 thousand; net loss narrowed to R$11,735 thousand from R$17,082 thousand, and EBITDA loss improved to R$10,691 thousand from R$14,742 thousand.

• Diabetes and thrombosis products grew commercially as Nova Lima validation and local Glargilin production advanced.

Financial highlights

• Gross profit fell 14% YoY to R$7,318 thousand, reflecting higher product costs as local production began and certain administrative expenses were reclassified to production costs.

• Sales, general and administrative, and other operating expenses totaled R$20,154 thousand, down 22.7% YoY, mainly due to lower marketing and administrative expenses.

• Net financial income was R$211 thousand versus R$320 thousand in 1Q24.

• Revenue was down 1% QoQ; gross profit rose 350% QoQ.

Segment performance

• Insulin glargine sales volume grew 25% YoY versus 9% for the market; LTM growth through Mar25 was 48% versus 14% for the market.

• Insulin glargine market share rose to 40% from 35% YoY; LTM share increased from 23% in Mar24 to 30% in Mar25. Glargilin grew 113.3% YoY and reached 54.1% share of the insulin glargine market.

• Wosulin grew 185.8% YoY and reached 2.2% share; Ministry of Health deliveries rose 526.4%, while delayed supply limited volume to 7% of total sales.

• Enoxaparin private-market volume grew 24% YoY as the market contracted 8%; share rose to 3% from 2%. Ghemaxan grew 34.2% in the private channel and gained 1.1 pp share in anti-thrombotics.

• Private-market human insulin sales fell 98.3% YoY.